The Federal Communications Commission approved AST SpaceMobile’s application to modify its authorization to launch and operate a non‑geostationary orbit satellite system in low Earth orbit, allowing the company to deploy a constellation of up to 248 satellites that will provide supplemental coverage directly to unmodified mobile devices in the United States.
The order permits the use of premium 700 MHz and 800 MHz low‑band spectrum in coordination with Verizon, AT&T, and FirstNet, and expands the company’s international operations with feeder‑link and sub‑1 GHz direct‑to‑device spectrum rights.
The approval removes a key regulatory barrier, validating AST SpaceMobile’s technology and system design, and positions the company to begin commercial service and revenue generation. CEO Abel Avellan said the decision “marks an important step as we continue scaling our network and moving closer to commercial service.”
The regulatory win follows the BlueBird 7 satellite failure, which occurred when a Blue Origin launch vehicle could not place the satellite into its planned orbit. AST SpaceMobile has insurance for the lost satellite and continues production of subsequent satellites.
The approval strengthens partnerships with Verizon, AT&T, and FirstNet, potentially accelerating prepayment milestones and expanding service to first responders and government agencies. The 700/800 MHz spectrum offers superior penetration and coverage, giving AST SpaceMobile a competitive edge over other satellite‑to‑device providers such as Starlink Mobile and Project Kuiper.
AST SpaceMobile has guided for $150 million to $200 million in revenue for 2026, and the FCC approval is expected to accelerate that path. The company remains unprofitable but has a strong cash position and a high market capitalization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.